You can buy or sell Xenetic and other stocks, options, ETFs, and crypto commission-free!
Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. Read More The company was founded on August 9, 2011 and is headquartered in Framingham, MA. The listed name for XBIO is Xenetic Biosciences, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Nov 13, Pre-Market